Edition:
United Kingdom

Cellect Biotechnology Ltd (APOP.OQ)

APOP.OQ on NASDAQ Stock Exchange Capital Market

7.50USD
22 Feb 2018
Change (% chg)

$0.09 (+1.21%)
Prev Close
$7.41
Open
$7.36
Day's High
$7.50
Day's Low
$7.36
Volume
2,208
Avg. Vol
25,443
52-wk High
$13.50
52-wk Low
$5.90

Latest Key Developments (Source: Significant Developments)

Cellect Announces Opening Of Second Clinical Trial Site And Approval From Safety Board (DSMB) For Dose Escalation
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Cellect Biotechnology Ltd ::CELLECT ANNOUNCES OPENING OF A SECOND CLINICAL TRIAL SITE AND APPROVAL FROM SAFETY BOARD (DSMB) FOR DOSE ESCALATION.CELLECT BIOTECHNOLOGY - ‍SIGNED AGREEMENT WITH HADASSAH MEDICAL CENTER TO CONDUCT CLINICAL TRIALS ON CANCER PATIENTS IN CO'S ONGOING PHASE I/II STUDY​.CELLECT BIOTECHNOLOGY -‍ GOT APPROVAL FROM DSMB TO ESCALATE APOGRAFT FASL PROTEIN DOSAGE TO 25 NG/ML, ENROLL 3 ADDITIONAL PATIENTS FOR CLINICAL TRIAL​.  Full Article

Cellect Biotechnology reports Q3 ‍loss $0.02/shr​
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Cellect Biotechnology Ltd :Cellect Biotechnology Ltd provides corporate update and reports third quarter 2017 financial results.Cellect Biotechnology Ltd - qtrly ‍loss per share $0.02​.  Full Article

Cellect Biotechnology reports Q2 loss per share $0.01
Thursday, 1 Sep 2016 

Cellect Biotechnology Ltd : Cellect Biotechnology Ltd provides corporate update and reports second quarter 2016 financial results .Q2 loss per share $0.01.  Full Article

Cellect Biotechnology sees U.S. IPO of 1.3 mln American depositary shares
Tuesday, 26 Jul 2016 

Cellect Biomed Ltd :Cellect Biotechnology Ltd sees U.S. IPO of 1.3 million American depositary shares - SEC filing.  Full Article

Cellect Biomed files for U.S. IPO of up to $10 mln - SEC Filing
Thursday, 7 Jul 2016 

Cellect Biomed Ltd: Files for U.S. IPO of up to $10.0 million - SEC Filing . Intends to apply to list ADSS on Nasdaq capital market . Proposed IPO price is an estimate solely for purpose of calculating sec registration fee .Rodman Renshaw and Chardan Capital Markets are the underwriters to IPO.  Full Article

No consensus analysis data available.